Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: A prototype oral male hormonal contraceptive

Andrology

Volumn 2, Issue 4, 2014, Pages 579-587

  Surampudi, P ^a   Page, S T ^b   Swerdloff, R S ^a   Nya Ngatchou, J J ^b   Liu, P Y ^a   Amory, J K ^b   Leung, A ^a   Hull, L ^a   Blithe, D L ^c   Woo, J ^c   Bremner, W J ^b   Wang, C ^a  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Androgens; Contraception; Pharmacokinetics; Progesterone progestagens

Indexed keywords

ANDROGEN; ASPARTATE AMINOTRANSFERASE; DIMETHANDROLONE UNDECANOATE; GONADOTROPIN; MALE CONTRACEPTIVE AGENT; PLACEBO; SEX HORMONE; UNCLASSIFIED DRUG; 7ALPHA,11BETA-DIMETHYL-19-NORTESTOSTERONE; DIMETHANDROLONE-UNDECANOATE; FAT INTAKE; NANDROLONE;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; GONADOTROPIN BLOOD LEVEL; HORMONAL CONTRACEPTION; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POWDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN; ADMINISTRATION AND DOSAGE; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; FAT INTAKE; FOOD; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, MALE; DIETARY FATS; DOUBLE-BLIND METHOD; FASTING; FOOD; GONADOTROPINS; HUMANS; MALE; MIDDLE AGED; NANDROLONE;

EID: 84904611423     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/j.2047-2927.2014.00216.x     Document Type: Article

References (42)

1. Anawalt BD, Herbst KL, Matsumoto AM, Mulders TM, Coelingh-Bennink HJ & Bremner WJ. (2000) Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Ferti Steril 74, 707-714.
2. Attardi BJ, Hild SA & Reel JR. (2006) Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 147, 3016-3026.
3. Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA & Reel JR. (2008) Dimethandrolone (7alpha, 11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. J Steroid Biochem Mol Biol 110, 214-222.
4. Attardi BJ, Hild SA, Koduri S, Pham T, Pessaint L, Engbring J, Till B, Gropp D, Semon A & Reel JR. (2010) The potent synthetic androgens, dimethandrolone (7alpha, 11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone, do not require 5alpha-reduction to exert their maximal androgenic effects. J Steroid Biochem Mol Biol 32, 530-540.
5. Attardi BJ, Engbring JA, Gropp D & Hild SA. (2011) Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits. J Androl 32, 530-540.
6. Bagchus WM, Hust R, Maris F, Schnabel PG & Houwing NS. (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23, 319-325.
7. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ & Matsumoto AM. (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81, 757-762.
8. Boyer JL, Preisig R, Zbinden G, de Kretser DM, Wang C & Paulsen CA. (1976) Guidelines for assessment of potential hepatotoxic effects of synthetic androgens, anabolic agents and progestagens in their use in males as antifertility agents. Contraception 13, 461.
9. Buchter D, von Eckardstein S, von Eckardstein A, Kamischke A, Simoni M, Behre HM, Nieschlag E. (1999) Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 84, 1244-1249.
10. Burnett-Bowie SA, McKay EA, Lee H & Leder BZ. (2009) Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 94, 4785-4792.
11. Cook CE & Kepler JA. (2005) 7alpha, 11beta-dimethyl-19-nortestosterone: a potent and selective androgen response modulator with prostate-sparing properties. Bioorg Med Chem Lett 15, 1213-1216.
12. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ & Leder BZ. (2013) Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369, 1011-1022.
13. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ & Zhang GY. (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88, 562-568.
14. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, Bo L, Xiong C, Wang X, Liu X, Peng L & Yao K. (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 94, 1910-1915.
15. Heinemann K, Saad F, Wiesemes M, White S & Heinemann L. (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20, 549-556.
16. Hild SA, Marshall GR, Attardi BJ, Hess RA, Schlatt S, Simorangkir DR, Ramaswamy S, Koduri S, Reel JR & Plant TM. (2007) Development of l-CDB-4022 as a nonsteroidal male oral contraceptive: induction and recovery from severe oligospermia in the adult male cynomolgus monkey (Macaca fascicularis). Endocrinology 148, 1784-1796.
17. Hild SA, Attardi BJ, Koduri S, Till BA & Reel JR. (2010) Effects of synthetic androgens on liver function using the rabbit as a model. J Androl 31, 472-481.
18. Horst HJ, Holtje WJ, Dennis M, Coert A, Geelen J & Voigt KD. (1976) Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr 54, 875-879.
19. Khosla S & Bilezikian JP. (2003) The role of estrogens in men and androgens in women. Endocrinol Metab Clin North Am 32, 195-218.
20. Khosla S, Melton LJ 3rd, Atkinson EJ & O'Fallon WM. (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86, 3555-3561.
21. Liu PY, Swerdloff RS, Anawalt BD, Anderson RA, Bremner WJ, Elliesen J, Gu YQ, Kersemaekers WM, McLachlan RI, Meriggiola MC, Nieschlag E, Sitruk-Ware R, Vogelsong K, Wang XH, Wu FC, Zitzmann M, Handelsman DJ & Wang C. (2008) Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 93, 1774-1783.
22. Loves S, de Jong J, van Sorge A, Telting D, Tack CJ, Hermus A, Westerterp K & de Boer H. (2013) Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur J Endocrinol 169, 705-714.
23. Meriggiola MC, Farley TM & Mbizvo MT. (2003) A review of androgen-progestin regimens for male contraception. J Androl 24, 466-483.
24. Murray-Lyon IM, Westaby D & Paradinas F. (1977) Hepatic complications of androgen therapy. Gastroenterology 73, 1461.
25. Nieschlag E. (2010) Clinical trials in male hormonal contraception. Contraception 82, 457-470.
26. Nieschlag E, Hoogen H, Bolk M, Schuster H & Wickings EJ. (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception 18, 607-614.
27. Page ST, Amory JK & Bremner WJ. (2008) Advances in male contraception. Endocr Rev 29, 465-493.
28. Roth MY, Ilani N, Wang C, Page ST, Bremner WJ, Swerdloff RS, Dart C, Sitruk-Ware R, Kumar N, Blithe D & Amory JK. (2013) Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone((R)) gels. Andrology 1, 899-905.
29. Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, Goh VH, Ridgway EC & Wierman ME. (2011) Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 76, 177-182.
30. Schnabel PG, Bagchus W, Lass H, Thomsen T & Geurts TB. (2007) The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf) 66, 579-585.
31. Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJ & Charman WN. (2003) Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther 306, 925-933.
32. Shiraishi S, Lee PW, Leung A, Goh VH, Swerdloff RS & Wang C. (2008) Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. Clin Chem 54, 1855-1863.
33. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J & Berman N. (2000) Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 85, 4500-4510.
34. Trussell J. (2009) Understanding contraceptive failure. Best Pract Res Clin Obstet Gynaecol 23, 199-209.
35. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI & Handelsman DJ. (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88, 4659-4667.
36. Vermeulen A, Verdonck L & Kaufman JM. (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84, 3666-3672.
37. Wang C & Swerdloff RS. (2004) Male hormonal contraception. Am J Obstet Gynecol 190, S60-S68.
38. Westaby D, Ogle SJ, Paradinas FJ, Randell JB & Murray-Lyon IM. (1977) Liver damage from long-term methyltestosterone. Lancet 2, 262.
39. World Health Organization Task Force on Methods for the Regulation of Male Fertility. (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 336, 955-959.
40. World Health Organization Task Force on Methods for the Regulation of Male Fertility. (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Ferti Steril 65, 821-829.
41. Yin A, Alfadhli E, Htun M, Dudley R, Faulkner S, Hull L, Leung A, Bross R, Longstreth J, Swerdloff R & Wang C. (2012a) Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men. J Androl 33, 1282-1290.
42. Yin AY, Htun M, Swerdloff RS, Diaz-Arjonilla M, Dudley RE, Faulkner S, Bross R, Leung A, Baravarian S, Hull L, Longstreth JA, Kulback S, Flippo G & Wang C. (2012b) Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. J Androl 33, 190-201.